Plain-English translation of NCT06934642 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a small pilot study testing how affects the liver in people with metabolic dysfunction-associated steatotic liver disease (MASLD)—a condition where fat builds up in the liver, often linked to obesity and diabetes. is a medication already approved to help with type 2 diabetes and weight loss, and early research suggests it may also help the liver. This study will watch how the medication affects liver health markers over one year.
Fatty liver disease is becoming increasingly common in people with obesity and diabetes, and it can lead to serious liver damage over time. While this medication shows promise for treating the condition, researchers need to study exactly how it works and how well it helps liver function in patients with this specific disease.
You likely qualify if…
You likely don't qualify if…
You would take the medication daily for 12 months while attending clinic visits every 3 months to check on your progress. You'll have blood work done at the start, halfway through (6 months), and at the end of the study, along with liver ultrasounds at the beginning and end. The study is small—only 8 participants total—so you'll receive close monitoring throughout.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States